# EDGAR Filing Document

**Accession Number:** 0001834645
**File Stem:** 0001193125-23-020525
**Filing Date:** 2023-1
**Character Count:** 6269
**Document Hash:** 90efa60235983f1f3e7a21b8c9419e03
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-020525.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001193125-23-020525

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Peak Bio, Inc.
- **CENTRAL INDEX KEY:** 0001834645
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 852448157
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3350 W BAYSHORE RD. SUITE 100
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303
- **BUSINESS PHONE:** (650) 549-9103

**MAIL ADDRESS:**
- **STREET 1:** 3350 W BAYSHORE RD. SUITE 100
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ignyte Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201202

**Peak Bio, Inc.** 

3350 W. Bayshore Rd., Suite 100

Palo Alto, CA 94303

January 31, 2023

**VIA EDGAR** 

Attention: Jimmy McNamara

Christine Westbrook

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Peak Bio, Inc.**  |

---

**Amendment No. 1 to Registration Statement on Form S-1** 

**Filed January 5, 2023** 

**File No. 333-268801** 

Ladies and Gentlemen:

This letter sets forth the response of Peak Bio, Inc. (the "***Company***" or "***Peak Bio***") to the comments of the staff of the Division of Corporation Finance (the "***Staff***") of the Securities and Exchange Commission set forth in your letter dated January 18, 2023 (the "***Comment Letter***"), with respect to the above referenced Amendment No. 1 to Registration Statement on Form S-1 (the "***Registration Statement***"). Concurrently with the submission of this letter, the Company is filing Amendment No. 2 to the Registration Statement (the "***Amended Registration Statement***"). In addition to addressing the comments raised by the Staff in the Comment Letter, the Company has included other revisions and updates to its disclosure in the Amended Registration Statement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Amended Registration Statement.

Set forth below is the Company's response to the Staff's comments. For the Staff's convenience, we have incorporated your comments into this response letter in italics.

<u>Prospectus Summary</u> 

<u>Background page 4</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.* *We note your disclosure indicating that certain subscription agreements were effective as of October 31, 2022. To the extent you have not done so, ensure that you disclose the material terms of each of the financing transactions entered into in connection with the closing of the business combination, including as examples only, the New PIPE Shares, PIPE Financing Warrants, Bridge Loan PIPE Shares, the convertible note referenced on page 85 and payment agreements referenced on page F-29.* 

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on pages 5, 6 and 89 of the Amended Registration Statement in response.

------

<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>

<u>Funding Requirements, page 96</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*2.* *We note your response to prior comment 6 and your disclosure that you enhanced your liquidity position by, among others, a $750,000 sale of stock under a previously disclosed forward share purchase agreement with Frost Gamma Investments Trust. We note your disclosure on the cover page that an amount of $749,127 that was held in escrow was released to the company in connection with the forward share purchase agreement. Please revise to clarify your reference to this transaction as a stock sale that enhanced your liquidity position.* 

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on page 97 of the Amended Registration Statement in response.

<u>General</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*3.* *We note from your disclosure in Item 3.01 of Form 8-K, filed January 9, 2023, that it appears your NASDAQ listing was suspended. Please update your disclosure accordingly to discuss the suspension and the appeal and review process. In addition, please note that unless the shares are listed on a national securities exchange or quoted on the OTC Bulletin Board, OTCQX, or OTCQB, your selling shareholders must sell at a fixed price. Refer to Item 501(b)(3) of Regulation S-K.* 

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on the prospectus cover page and pages 7, 8, 10, 66, 78, 185, 195, 198 and F-91 of the Amended Registration Statement in response.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*4.* *We note from your disclosure in Item 7.01 of Form 8-K, filed November 2, 2022, that Chardan Capital Markets LLC withdrew from its role as financial advisor to Ignyte and will no longer receive any financial advisory fee. Please update your disclosure accordingly to discuss this withdrawal.* 

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on pages 5 of the Amended Registration Statement in response.

\*\*\*\*\*

------

We respectfully request the Staff's assistance in completing the review of the Amended Registration Statement as soon as possible. Please contact Andrew P. Gilbert of DLA Piper LLP (US) at (973) 520-2553 or Scott A. Cowan of DLP Piper LLP (US) at (973) 520-2554 with any questions or further comments regarding the responses to the Staff's comments.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| PEAK BIO, INC. | PEAK BIO, INC. |
| By: | /s/ Stephen LaMond |
| Name: Stephen LaMond | Name: Stephen LaMond |
| Title: Interim Chief Executive Officer | Title: Interim Chief Executive Officer |

---

cc: Stephen LaMond, Peak Bio, Inc.

Andrew P. Gilbert, DLA Piper LLP (US)

Scott A. Cowan, DLA Piper LLP (US)